Trans-arterial chemoperfusion for the treatment of liver metastases of breast cancer and colorectal cancer: Clinical results in palliative care patients

Table 1 Indications and contraindications of trans-arterial chemoperfusion

Indications

Unresectable liver metastases

Liver-dominant metastatic disease

Minimum of three different chemotherapies before

No systemic chemotherapy available

Symptomatic liver metastases

Contraindications

ECOG >1

Tumour burden of the liver > 75%

Poor liver function (quick < 40%, PTT < 45 s, albumin < 2 g/dL)

Extensive amounts of ascites

Obstructive icterus (bilirubin > 3 mg/dL)

Acute infection

Myelodepression (leucocytes < 2000/mL, platelets < 100000/μL)

Limited kidney function (creatinine > 2 mg/dL)

Extensive heart insufficiency ( > NYHA II)

ECOG: Eastern Cooperative Oncology Group; PTT: Prothrombin time test; NYHA: New York Heart Association.

Table 2 Response Evaluation Criteria in Solid Tumors

Category	RECIST
CR	Disappearance of all tumour lesions
PR	Reduction of > 30% in total tumour size
SD	Reduction of < 30% or a growth of < 20%
PD	Growth of > 20% or occurrence of new lesions

RECIST: Response Evaluation Criteria in Solid Tumors; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease.

Table 3 Responders vs non-responders¹n (%)

Carcinoma	Therapy response (CR + PR + SD)	Non responders (PD)
CRC	9 (52.9)	8 (47.1)
Breast-Ca	16 (84.2)	3 (15.8)

¹The difference between responders and non-responders reached statistical significance (P = 0.042, χ² test). CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; CRC: Colorectal cancer.

Table 4 Number of treatments¹

Carcinoma	Mean	Median	Min	Max
CRC	5.2	5	3	8
Breast-Ca	7.7	7	3	17

¹The difference reached significance (P = 0.0458, Mann-Whitney U test). CRC: Colorectal cancer.

Table 5 Partial response, stable disease, progressive disease

Carcinoma	Partial response	Stable disease	Progressive disease	Total
Colon	2	7	8	17
Breast	7	9	3	19